PL2172471T3 - Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA - Google Patents

Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA

Info

Publication number
PL2172471T3
PL2172471T3 PL09177121T PL09177121T PL2172471T3 PL 2172471 T3 PL2172471 T3 PL 2172471T3 PL 09177121 T PL09177121 T PL 09177121T PL 09177121 T PL09177121 T PL 09177121T PL 2172471 T3 PL2172471 T3 PL 2172471T3
Authority
PL
Poland
Prior art keywords
hmg
coa reductase
reductase inhibitors
preparing intermediates
intermediates
Prior art date
Application number
PL09177121T
Other languages
English (en)
Inventor
Vinod Kumar Kansal
Brijnath P Chaurasia
Hitesh K Patel
Vrajlal Gothalia
Hiren Gandhi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL2172471T3 publication Critical patent/PL2172471T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrane Compounds (AREA)
PL09177121T 2007-04-18 2008-04-18 Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA PL2172471T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92521607P 2007-04-18 2007-04-18
US93192607P 2007-05-24 2007-05-24
US6667808P 2008-02-21 2008-02-21
US6909908P 2008-03-11 2008-03-11
EP08743067A EP2032586A2 (en) 2007-04-18 2008-04-18 A process for preparing intermediates of hmg-coa reductase inhibitors
EP09177121A EP2172471B1 (en) 2007-04-18 2008-04-18 A process for preparing intermediates of HMG-CoA reductase inhibitors

Publications (1)

Publication Number Publication Date
PL2172471T3 true PL2172471T3 (pl) 2013-08-30

Family

ID=39588172

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09177121T PL2172471T3 (pl) 2007-04-18 2008-04-18 Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA

Country Status (8)

Country Link
US (4) US7687660B2 (pl)
EP (5) EP2062903A1 (pl)
JP (2) JP2009538831A (pl)
KR (2) KR20090018964A (pl)
ES (1) ES2415206T3 (pl)
MX (1) MX2008016244A (pl)
PL (1) PL2172471T3 (pl)
WO (2) WO2008130638A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2172471T3 (pl) * 2007-04-18 2013-08-30 Teva Pharma Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA
WO2011106546A1 (en) * 2010-02-25 2011-09-01 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin intermediate
BR112012022209A2 (pt) * 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US9029627B2 (en) 2010-03-04 2015-05-12 Masaru Okabe Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
CN102212081B (zh) * 2010-12-30 2013-11-13 华润双鹤药业股份有限公司 一种用于他汀类药物合成的手性中间体的制备方法
CN102358747B (zh) * 2011-08-30 2012-09-19 浙江宏元药业有限公司 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法
CA2857078A1 (en) 2011-11-28 2013-06-06 Mylan Laboratories Ltd Process for producing chiral statin side chain intermediates employing candida/antarctica lipase b
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
US9518028B2 (en) 2013-07-16 2016-12-13 Suven Life Sciences Limited Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates
CN103483393B (zh) * 2013-09-05 2016-08-17 江苏兰健药业有限公司 一种用于他汀类药物合成的手性中间体的制备方法
CN103497212B (zh) * 2013-09-25 2015-11-18 浙江科技学院 一种瑞舒伐他汀钙中间体的制备方法
CN104262383B (zh) * 2014-03-31 2017-01-18 南京欧信医药技术有限公司 一种化合物的合成方法
CN104370953B (zh) * 2014-08-24 2017-01-18 浙江新东港药业股份有限公司 一种(r)‑叔丁基二甲基硅氧基‑戊二酸单酯的制备方法
KR101710976B1 (ko) * 2015-04-08 2017-02-28 임광민 키랄 화합물의 제조방법 및 이를 이용한 HMG-CoA 환원저해제의 제조방법
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009955A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료
EP4153564A1 (en) 2020-05-19 2023-03-29 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554455B1 (en) * 1991-06-19 1997-12-17 Shionogi Seiyaku Kabushiki Kaisha Optically active intermediate and production thereof
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
JP3272377B2 (ja) * 1991-07-30 2002-04-08 塩野義製薬株式会社 光学活性なグルタル酸エステル誘導体の光学分割法
JP3091022B2 (ja) * 1992-07-16 2000-09-25 塩野義製薬株式会社 グルタル酸誘導体の製造方法
JP2940395B2 (ja) * 1993-03-30 1999-08-25 宇部興産株式会社 オキシグルタル酸エステル誘導体の製法
DE69424463T2 (de) * 1993-03-30 2000-09-14 Ube Industries Verfahren zur Herstellung von Ester-Derivaten der Oxyglutar-Säure
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
WO2003064392A1 (en) 2002-01-31 2003-08-07 Novartis Ag Process for the manufacture of hmg-coa reductase inhibitors
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
AR039836A1 (es) 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
CZ298330B6 (cs) 2004-07-19 2007-08-29 Zentiva, A. S. Zpusob výroby 4-(4-fluorfenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5-pyrimidinkarbaldehydu a jeho použití
EP1634870A1 (en) 2004-08-27 2006-03-15 Zhejiang Hisun Pharmaceutical Co. Ltd. Process and intermediates for the selective synthesis of Fluvastatin
CN1807417A (zh) 2005-01-18 2006-07-26 何如钧 新型无水无结晶型态的罗伐他汀钙盐
CN100351240C (zh) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 瑞舒伐他汀钙的合成方法
KR100945763B1 (ko) * 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
CN1307187C (zh) 2005-05-16 2007-03-28 浙江海正药业股份有限公司 瑞舒伐他汀及其中间体的制备方法
EP1919880A2 (en) 2005-08-16 2008-05-14 Teva Pharmaceutical Industries Ltd. Rosuvastatin calcium with a low salt by-product content
CA2625290A1 (en) * 2005-10-04 2007-04-12 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
CN1958593B (zh) 2005-11-03 2010-05-05 上海医药工业研究院 一种用于合成瑞舒伐他汀钙的中间体的制备方法
CN1821242B (zh) 2006-02-16 2012-03-07 亚邦化工集团有限公司 制备二羟基酸HMG-CoA还原酶抑制剂的新方法
WO2008059519A2 (en) 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
WO2008044243A2 (en) 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2079712A2 (en) 2006-10-31 2009-07-22 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2008072078A1 (en) 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
WO2008093205A2 (en) 2007-01-31 2008-08-07 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of rosuvastatin intermediate
CA2677809A1 (en) 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
PL2172471T3 (pl) 2007-04-18 2013-08-30 Teva Pharma Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA

Also Published As

Publication number Publication date
JP2009531466A (ja) 2009-09-03
WO2008130678A2 (en) 2008-10-30
EP2172471B1 (en) 2013-03-27
EP2032587A2 (en) 2009-03-11
EP2172471A2 (en) 2010-04-07
WO2008130678A3 (en) 2008-12-11
US7687660B2 (en) 2010-03-30
US7964748B2 (en) 2011-06-21
ES2415206T3 (es) 2013-07-24
WO2008130638A2 (en) 2008-10-30
US20090209779A1 (en) 2009-08-20
WO2008130638A3 (en) 2008-12-18
US20090076271A1 (en) 2009-03-19
JP2009538831A (ja) 2009-11-12
US20100160663A1 (en) 2010-06-24
KR20090018964A (ko) 2009-02-24
KR20090033183A (ko) 2009-04-01
EP2032586A2 (en) 2009-03-11
MX2008016244A (es) 2009-04-17
EP2093230A1 (en) 2009-08-26
US20090076292A1 (en) 2009-03-19
EP2062903A1 (en) 2009-05-27
EP2172471A3 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
PL2172471T3 (pl) Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA
HK1223370A1 (zh) 製備整合酶抑制劑的方法和中間體
AP2785A (en) Process and intermediates for preparing integrase inhibitors
HK1243626A1 (zh) 氨基甲酰基吡啶酮hiv整合酶抑制劑和中間體的合成
EP2588474A4 (en) PROCESS FOR PREPARING HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF
IL210253A0 (en) Method of searching for a thermal target
IL251372A0 (en) A process for the synthesis of inhibitors of e1 enzyme activators
PT3617194T (pt) Processos e intermediários para inibidores carbamoilpiridona da integrase do vih
ZA201102510B (en) Slurry process for synthesis of biophosphites
ZA201208363B (en) Novel intermediates for the preparation of hmg-coa reductase inhibitors
PL2279175T3 (pl) Sposób wytwarzania związków pośrednich naftalen-2-ylopirazol-3-onu użytecznych w syntezie inhibitorów receptorów sigma
EP2123780A4 (en) PROCESS FOR THE PRODUCTION OF STEEL SHEETS FOR METALLIC BOXES
IL219274A0 (en) Process for synthesis of intermediates useful for making substituted indazole and azindazole compounds
EP2351762A4 (en) A NEW PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING A INTERMEDIATE PRODUCT OF AN HMG COA REDUCTASE INHIBITOR
EP2493899B8 (de) Verfahren zur herstellung von metallverbindungen
HK1157778A1 (en) A process for the preparation of tert-butyl (r)-3-vinylpyrrolidine-1- carboxylate and intermediates therefor
SI1937696T1 (sl) Postopek za pripravo zaviralcev HMG-CoA reduktaz
HUP0700668A2 (en) Process for producing intermediates of rosuvastatin
IL191919A0 (en) Process for preparing a crystalline form of atorvastatin hemi-calcium
ZA201200348B (en) A process for the synthesis of naratriptan
EP2285804A4 (en) METHOD FOR MANUFACTURING PALIPERIDONE INTERMEDIATES
SI2172471T1 (sl) Postopek za pripravo vmesne spojine inhibitorjev HMG-CoA reduktaze
EP2291077A4 (en) METHOD OF MANUFACTURING RHO-KINASE INHIBITOR COMPOUNDS
ZA201003638B (en) Method for producing a painted steel sheet product of high strengh
PL389114A1 (pl) Sposób syntezy prekursorów samoprzylepnego kleju strukturalnego na bazie poliakrylanów